Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2024) 99 EP571 | DOI: 10.1530/endoabs.99.EP571

ECE2024 Eposter Presentations Reproductive and Developmental Endocrinology (78 abstracts)

Short and long-term efficacy of minoxidil on beard growth in a group of assigned female at birth transgender people on gender affirming hormone therapy

Lorenzo Marinelli 1 , Andreina Bichiri 1 , Ezio Ghigo 1 & Giovanna Motta 1


1University of Turin, Department of Medical Sciences, Turin, Italy


Introduction: Minoxidil is a vasodilator drug used as topical treatment of androgenetic alopecia; however, its efficacy for beard enhancement is reported in cisgender men and in a case-report of a transgender assigned female at birth (t-AFAB) adolescent. This study aims to evaluate the short- and long-term efficacy of topical minoxidil in a group of t-AFAB people on gender affirming hormone therapy (GAHT) with testosterone.

Materials and methods: Sixteen t-AFAB clients with an uncomplete beard development, on GAHT for at least for 6 months, were enrolled at CIDIGEM gender team, Turin. They used Minoxidil 2% 2 ml/day on the interested facial areas for at least 3 consecutive months. Before starting (T0), after 3 (T3) 6 (T6) and 12 months (T12) we evaluated facial hair growth using Ferriman-Gallwey modified score (FGm). Hair gowth pattern and side effects were subjectively reported.

Results: At T0, recruited clients were 26 (2.7) years old, and they were on GAHT for 18,5 [15-54] months; we observed a FGm of 2 [1-2] at the prolabium and 2 [1-2] at the chin. Compared to T0, we observed a statistically significant difference on the pair matched evaluation at T3 (median prolabium FGm 3 [2.25-4] and chin 3.5 [3-4]; P<0.05) and at T6 (FGm 3.5 [3-4] - prolabium and 4 [3.25-4] - chin; P≤0.002). No major side effects were reported. At T6 73% of the sample stopped minoxidil. At T12 we observed substantial stability of the obtained results (chin FGm 4 [3.75-4] and prolabium FGm 4 [3-4]; P>0.05), even if 2 people reported a slower hair growth since suspension. The other 27% kept using minoxidil due to unsatisfaction of the results or fear of regression.

Conclusion: The use of Minoxidil 2% in a group of t-AFAB people on GAHT showed at 3 and 6 months of use a significative beard growth enhancement. Stopping the therapy at 6 months seemed to maintain the obtained improvements during the subsequent months even if the beard speed growth may be impaired.

Volume 99

26th European Congress of Endocrinology

Stockholm, Sweden
11 May 2024 - 14 May 2024

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.